Trial
NCT03938337
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
University of Alabama at Birmingham
Collaborators
—
Condition
Head and Neck Cancer
Intervention
Cohort 1 Not Previously Treated
Why stopped
Sponsor terminated study due to higher incidence of pulmonary toxicity than expected, including death
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-09